• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Bristol-Myers Squibb Co.

Viz.ai partners with Bristol Myers Squibb on early hypertrophic cardiomyopathy detection

March 3, 2023 By Sean Whooley

Viz.ai announced today that it entered into a multi-year agreement with Bristol Myers Squibb (NYSE:BMY) for detecting hypertrophic cardiomyopathy. The partnership seeks to deploy an AI algorithm and the Viz HCM provider workflow software. This can help identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy. San Francisco-based Viz.ai […]

Filed Under: Business/Financial News, Cardiovascular, Diagnostics, Digital Health, Health Technology, Software / IT Tagged With: Bristol-Myers Squibb Co., Viz.ai

The top 5 pharma firms by reputation

April 12, 2021 By Brian Buntz

Recent research from reputation data specialist RepTrak (Boston) indicates that the pharma industry had the largest year-over-year reputational improvement of any sector, according to its roundup of top 100 corporations. The sector saw significant gains in consumers’ perception of its citizenship and governance.  Now ranked eighth overall, the pharma industry came in just ahead of […]

Filed Under: Pharmaceutical Tagged With: Bristol-Myers Squibb Co., Eli Lilly & Co., Novo Nordisk, pharma industry, RepTrak, reputation, Roche, Sanofi

NIH launches drug trial for deadly cytokine storm

October 16, 2020 By Sean Whooley

The National Institutes of Health today launched a Phase 3 clinical trial to evaluate three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes proteins that trigger inflammation, otherwise known as a cytokine storm, which can lead to acute respiratory distress syndrome, multiple […]

Filed Under: Business/Financial News, Clinical Trials, Featured, Pharmaceutical Tagged With: AbbVie, Bristol-Myers Squibb Co., coronavirus, COVID-19, Janssen Pharmaceuticals, Johnson & Johnson, National Institutes of Health (NIH)

iRhythm touts AFib study

December 18, 2019 By Sean Whooley

iRhythm Technologies (NSDQ:IRTC) announced that it is participating in a new Bristol-Myers Squibb–Pfizer (NYSE:PFE) Alliance study for reducing stroke by screening for undiagnosed atrial fibrillation in elderly individuals. The goal of the “Guard-AF” study is to determine if earlier detection of AFib can impact the rate of stroke through screening previously undiagnosed people who are at least […]

Filed Under: Cardiovascular, Clinical Trials, Featured Tagged With: Bristol-Myers Squibb Co., iRhythm Technologies Inc., Pfizer

Fitbit inks cardiovascular monitoring deal with pharma alliance

October 17, 2019 By Sean Whooley

The Bristol-Myers Squibb (NYSE:BMY)-Pfizer (NYSE:PFE) Alliance said today that it is working with Fitbit (NYSE:FIT) to improve earlier detection of atrial fibrillation in individuals with an increased risk of stroke. Fitbit and the alliance plan to work together on the development of educational content and guidance in support of people at increased risk for Afib. Fitbit is seeking […]

Filed Under: Business/Financial News, Cardiovascular, Software / IT Tagged With: Bristol-Myers Squibb Co., Fitbit, Pfizer

Taris Bio, Bristol-Myers Squibb launch bladder cancer trial

July 12, 2019 By Nancy Crotti

Taris Biomedical has announced the dosing of the first patient in a study of its TAR-200 system plus a programmed immune checkpoint inhibitor for the treatment of muscle-invasive bladder cancer (MIBC). The TAR-200 system continuously delivers the chemotherapy drug gemcitabine in the bladder for multiple weeks. The combination with Bristol-Myers Squibb’s Opdivo (nivolumab) will be assessed for […]

Filed Under: Business/Financial News, Clinical Trials, Implants, Oncology, Urology Tagged With: Bristol-Myers Squibb Co., Taris Biomedical

Report: Pharma companies kick off new year with price hikes

January 2, 2019 By Sarah Faulkner

Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Get the full story at our […]

Filed Under: Business/Financial News, Pharmaceutical, Wall Street Beat Tagged With: Allergan, Biogen, Bristol-Myers Squibb Co., Eli Lilly & Co., Pfizer

Sanuwave confirms acting CEO Richardson as company head | Personnel Moves – December 12, 2018

December 12, 2018 By Fink Densford

Sanuwave said late last month that it lifted acting CEO and board chair Kevin Richardson to a permanent position in the corner office. Richardson joined the Suwanee, Ga.-based company in 2009 as board chair, and has served as acting CEO since 2014. He also served as managing partner of investment management firm Prides Capital from […]

Filed Under: Business/Financial News, Featured Tagged With: Bose Corp., Bristol-Myers Squibb Co., Common Sensing, glympsebio, INSIGHTEC, Insulet, IsoRay, Merck, novadipbiosciences, Owens and Minor, rmsmedical, Sanuwave, Visioneering Technologies, Zimmer Biomet

Motus GI taps Moran as CEO | Personnel Moves – September 25, 2018

September 25, 2018 By Fink Densford

Motus GI said today that it named Timothy Moran as its new chief executive officer, effective October 1, replacing former CEO Mark Pomeranz who will assume the role of president and COO. Moran has previously served ConvaTec‘s (LON:CTEC) Americas president and helped lead the company through its initial public offering in 2016. Prior to ConvaTec, Moran spent […]

Filed Under: Business/Financial News Tagged With: Allurion Technologies, Baxter, biomedgps, Bristol-Myers Squibb Co., ConvaTec, Covidien, Integra LifeSciences, Lumicell, Mallinckrodt, MedX Health, MOTUS GI, Myomo Inc, National Institutes of Health (NIH), Natus Medical Inc., northstarmedicaltechnologies, Personnel Moves, Pursuit Vascular, ReWalk Robotics

New Abingworth fund beats expectations

July 10, 2018 By Nancy Crotti

Lifesciences investment group Abingworth Bioventures has closed its latest fund, Abingworth Bioventures VII (ABV VII) at $315 million. The fund — Abingworth’s 12th invested in companies in Europe and the U.S. —  exceeded its target of $300 million.  The firm has more than $1.2 billion under management. The fund invests broadly across all stages of development, […]

Filed Under: Business/Financial News, Wall Street Beat Tagged With: Abingworth, alexionpharmaceuticals, Avillon, Bristol-Myers Squibb Co., CRISPR Therapeutics, GammaDelta Therapeutics, SFJ Pharmaceuticals

Bristol-Myers Squibb, Illumina to develop companion diagnostics for immunotherapies

April 16, 2018 By Sarah Faulkner

Bristol-Myers Squibb (NYSE:BMY) is joining forces with Illumina (NSDQ:ILMN) to develop and commercialize diagnostic tests to support Bristol’s portfolio of cancer drugs. The companies announced last week that they plan to develop an assay to measure predictive genomic biomarkers, like tumor mutation burden, that could help doctors identify patients that will benefit from Bristol’s immunotherapies. Get the full […]

Filed Under: Diagnostics, Oncology, Pharmaceutical, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Illumina Inc.

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy